Linagliptin Krka

Linagliptin, the active ingredient in Linagliptin Krka, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral administration. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used as part of a comprehensive diabetes treatment plan.

GNH USA supplies Linagliptin Krka as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards and supporting therapeutic needs across diverse healthcare settings.

Linagliptin is a DPP‑4 inhibitor used in the treatment of type 2 diabetes mellitus and related therapeutic strategies.

- Type 2 diabetes mellitus: improves glycaemic control as monotherapy or in combination with other antidiabetic agents. - Adjunct to diet and exercise: enhances insulin secretion and reduces glucagon levels to aid blood glucose management. - Combination therapy with metformin: provides additional HbA1c reduction in patients inadequately controlled on metformin alone.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient mild to moderate headache. - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea. - Dizziness: occasional light‑headedness. - Back pain: occasional musculoskeletal discomfort.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic injury: abnormal liver function tests. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas.

Linagliptin should be used with clinical vigilance in the following situations: - Renal impairment: dose adjustment may be required; monitor renal function. - Hepatic impairment: use with caution; monitor liver enzymes. - Risk of hypoglycaemia: avoid when combined with insulin or sulfonylureas. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Cardiovascular disease: no specific contraindication but monitor overall cardiovascular status. - Store at room temperature: keep in the original container, protect from moisture and light.

Linagliptin may interact with several medicines; clinical assessment is recommended.

Major Interactions (Avoid): - Insulin: increased risk of hypoglycaemia. - Sulfonylureas: heightened hypoglycaemia potential. - Strong CYP3A4 inhibitors: may raise linagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce linagliptin exposure. - Diuretics: monitor blood pressure and electrolytes. - ACE inhibitors: no significant interaction but renal function should be observed.